VRX Memo: Will Cut Third-Party Sales Force For Addyi When Contract Ends April 15, Planning Sales Effort Re-Launch


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Reuters reported after Monday's market close that Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plans on cutting its sales force for Addyi, a treatment aimed at female sexual dysfunction.

Reuters noted that an outside sales force handles sales for Addyi, which fell under Valeant's corporate umbrella following the company's $1 billion acquisition of Sprout Pharmaceuticals.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Reuters noted that it has seen an internal memo that discussed the matter and Valeant's decision to not renew the sales force's contract when it expires on April 15 is due to slow sales.

Shares of Valeant were trading lower by more than 1.50 percent early Tuesday morning.

Image Credit: Public Domain


Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.


Posted In: BiotechNewsHealth CareMoversGeneralAddyiReutersSprout PharmaceuticalsValeant